Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.
Level 2 - randomized trial
Randomized, placebo-controlled Phase IIa clinical trial
PubMed 33074237 · doi:10.3233/JAD-200896
What was done
A 12-month randomized, placebo-controlled Phase IIa clinical trial evaluated the safety, feasibility, and efficacy of oral benfotiamine in individuals with amnestic mild cognitive impairment (aMCI) or mild dementia due to Alzheimer's disease. Seventy participants were allocated to benfotiamine (n = 34) or placebo (n = 36). The primary clinical outcome was cognitive decline measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). Secondary outcomes were the Clinical Dementia Rating (CDR) score and brain glucose metabolism via fluorodeoxyglucose (FDG) PET uptake. Blood advanced glycation end products (AGE) were evaluated as an exploratory outcome.
What was found
Benfotiamine treatment was safe. Cognitive decline (increase in ADAS-Cog score) was 43% lower in the benfotiamine group compared to placebo, but this difference did not reach statistical significance (p = 0.125). Worsening in CDR score was 77% lower in the benfotiamine group compared to placebo (p = 0.034), with a stronger effect among APOE ε4 non-carriers. Benfotiamine significantly reduced the increase in blood AGE levels (p = 0.044, also stronger in APOE ε4 non-carriers) and produced a significant treatment effect on an exploratory FDG PET pattern score at 1 year (p = 0.002).
Why it matters
This study provides early clinical evidence that benfotiamine may slow functional decline and modulate relevant metabolic biomarkers in early-stage Alzheimer's disease, supporting larger Phase III investigations.
Limits
The trial had a small sample size (n = 70) and failed to achieve statistical significance on its primary cognitive endpoint (ADAS-Cog). Subgroup findings (APOE ε4 status) and FDG PET pattern outcomes were exploratory. The abstract does not report benfotiamine dosage, adherence rates, baseline characteristics, or specific safety and adverse event data.
Cited by
- contradicts Benfotiamine is converted into a water-soluble form in the blood and does not cross the blood-brain barrier effectively.